Long non‑coding RNA BACE1‑AS is an independent unfavorable prognostic factor in liver cancer
- Yuanyuan Nie
- Yanqing Li
- Yanhui Xu
- Yan Jiao
- Wei Li
Affiliations: Stem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Digestive, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130031, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
- Published online on: September 8, 2020 https://doi.org/10.3892/ol.2020.12065
Copyright: © Nie
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Liver cancer is one of the leading causes of cancer‑associated deaths with incidence rates continuously on the rise. Biomarkers are urgently required for early diagnosis and better prognostic classification, which is essential for risk stratification and optimizing treatment strategies in clinical settings. By analyzing the data extracted from The Cancer Genome Atlas database using R, the long noncoding RNA (lncRNA) β‑site APP‑cleaving enzyme 1 antisense (BACE1‑AS) was discovered to have both high diagnostic and prognostic values in liver cancer, which could serve as a promising biomarker in clinical settings. Precisely, lncRNA BACE1‑AS is significantly overexpressed in liver cancer and its levels vary within different subgroups, suggesting its tumorigenic role. Furthermore, higher BACE1‑AS predicts poorer overall survival and relapse‑free survival outcomes. Overall, the present study demonstrated that BACE1‑AS may be involved in liver cancer progression and could serve as a promising biomarker for diagnosis and prognostic evaluation.